If you’re researching weight loss medications in 2026, you’ve likely come across both retatrutide and tirzepatide. These next-generation GLP-1 agonists from Eli Lilly represent some of the most promising obesity treatments available or in development.
Based on our research, tirzepatide is the better choice for most people right now because it’s FDA-approved and available today, with proven 22.5% weight loss in Phase 3 trials. Retatrutide shows slightly higher weight loss (24.2%) in early trials, but it remains investigational and won’t be available until 2026-2027 at the earliest.
I’ve spent the past several months analyzing clinical trial data, FDA filings, and real user experiences to understand how these medications compare. Here’s what you need to know to make an informed decision.
Important Note: No head-to-head clinical trial directly comparing retatrutide to tirzepatide has been completed. The comparisons in this article are based on separate clinical trials with different study designs, durations, and patient populations.
ContentsTable of Contents
- 1Quick Comparison: Retatrutide vs Tirzepatide at a Glance→
- 2What Is Retatrutide?→
- 3Current Development Status→
- 4Phase 2 Trial Results→
- 5What Is Tirzepatide?→
- 6Available Doses and Administration→
- 7FDA-Approved Indications→
- 8Triple Agonist vs Dual Agonist: How They Work?→
- 9How Tirzepatide Works (Dual Agonist)?→
- 10How Retatrutide Works (Triple Agonist)?→
- 11Weight Loss Results: Clinical Trial Data Compared→
- 12Retatrutide Phase 2 Results→
- 13Tirzepatide SURMOUNT-1 Results→
- 14Important Context for Comparison→
- 15A1C Reduction and Diabetes Management→
- 16Diabetes Efficacy Data→
- 17Side Effects: Which Is Better Tolerated?→
- 18Side Effect Comparison→
- 19Why Retatrutide Shows Higher Side Effect Rates?→
- 20Availability: When Can You Get Each Medication?→
- 21Tirzepatide: Available Now→
- 22Telehealth Options for Tirzepatide Access→
- 23Tirzepatide Pricing→
- 24Retatrutide: Clinical Trials Only→
- 25How to Find Retatrutide Clinical Trials?→
- 26Expected Approval Timeline→
- 27Which Should You Choose: Retatrutide or Tirzepatide?→
- 28Choose Tirzepatide If:→
- 29Consider Waiting for Retatrutide If:→
- 30Can You Start Tirzepatide Now and Switch Later?→
- 31Frequently Asked Questions→
- 32Is retatrutide better than tirzepatide for weight loss?→
- 33When will retatrutide be FDA approved?→
- 34Can I get retatrutide now?→
- 35What is the difference between a triple and dual agonist?→
- 36Can you take retatrutide and tirzepatide together?→
- 37Does retatrutide have more side effects than tirzepatide?→
- 38How much does tirzepatide cost?→
- 39Is there a head-to-head trial comparing retatrutide and tirzepatide?→
- 40Final Verdict: Retatrutide vs Tirzepatide→
Quick Comparison: Retatrutide vs Tirzepatide at a Glance
Before diving into the details, here’s a side-by-side comparison of the key differences between these two medications:
| Feature | Retatrutide | Tirzepatide |
|---|---|---|
| Mechanism | Triple agonist (GLP-1 + GIP + Glucagon) | Dual agonist (GLP-1 + GIP) |
| FDA Status | Investigational (Phase 3 trials) | FDA Approved |
| Weight Loss | 24.2% at 48 weeks (Phase 2) | 22.5% at 72 weeks (Phase 3) |
| Availability | Clinical trials only | Available now by prescription |
| Brand Names | None (investigational) | Mounjaro, Zepbound |
| Expected Approval | 2026-2027 | Already approved |
| Dosing | Once weekly injection | Once weekly injection |
| Monthly Cost | Free (clinical trials) | $1,000-$1,350 (list price) |
The bottom line is straightforward: tirzepatide is the proven, available option right now. Retatrutide may offer slightly better results, but you’ll need to wait 2-3 years or enroll in a clinical trial to access it.
What Is Retatrutide?
Retatrutide (development name LY3437943) is an investigational triple receptor agonist medication developed by Eli Lilly for weight loss and type 2 diabetes treatment. It targets three hormone receptors: GLP-1, GIP, and glucagon.
This is significant because most current weight loss medications only target one or two receptors. The addition of the glucagon receptor may increase energy expenditure and fat burning beyond what dual agonists achieve.
Current Development Status
Retatrutide is currently in Phase 3 clinical trials as part of Eli Lilly’s TRIUMPH program. The key ongoing trials include:
- TRIUMPH-1: Obesity without diabetes
- TRIUMPH-2: Obstructive sleep apnea
- TRIUMPH-3: Knee osteoarthritis
- TRIUMPH-4: Type 2 diabetes
Based on typical FDA timelines, if Phase 3 results are positive, we might see FDA approval in late 2026 or 2027.
Phase 2 Trial Results
The Phase 2 obesity trial results were published in the New England Journal of Medicine in 2023. The study enrolled 338 participants and ran for 48 weeks.
At the highest dose (12mg), participants achieved a mean weight loss of 24.2%. This result generated significant excitement in the medical community and set high expectations for the Phase 3 program.
Triple Agonist: A medication that activates three hormone receptors simultaneously. Retatrutide targets GLP-1 (appetite suppression), GIP (insulin regulation), and glucagon (energy expenditure) receptors.
What Is Tirzepatide?
Tirzepatide is an FDA-approved dual receptor agonist medication that targets GLP-1 and GIP receptors. It’s sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for obesity).
Eli Lilly received FDA approval for Mounjaro in May 2022 and for Zepbound in November 2023. Since then, millions of prescriptions have been written, providing extensive real-world safety and efficacy data.
Available Doses and Administration
Tirzepatide comes in a convenient pre-filled pen with six dose options: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. Patients typically start at the lowest dose and gradually increase every 4 weeks.
The medication is administered as a once-weekly subcutaneous injection. Most patients find the auto-injection pen easy to use at home.
FDA-Approved Indications
Tirzepatide is currently approved for:
- Type 2 diabetes: As Mounjaro, for blood sugar control
- Chronic weight management: As Zepbound, for adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition
- Obstructive sleep apnea: As Zepbound, for moderate-to-severe OSA with obesity (approved 2024)
Dual Agonist: A medication that activates two hormone receptors. Tirzepatide targets GLP-1 (appetite suppression and slowed gastric emptying) and GIP (insulin regulation and enhanced GLP-1 effects) receptors.
Triple Agonist vs Dual Agonist: How They Work?
Understanding the mechanism of action helps explain why retatrutide may offer additional benefits beyond tirzepatide. Let me break down how each approach works.
How Tirzepatide Works (Dual Agonist)?
Tirzepatide activates two hormone receptors that work together to promote weight loss:
GLP-1 Receptor: This reduces appetite, slows stomach emptying (so you feel full longer), and improves insulin secretion when blood sugar is elevated.
GIP Receptor: This enhances insulin sensitivity and amplifies the effects of GLP-1. GIP also appears to improve fat metabolism, though the exact mechanisms are still being studied.
The combination is more effective than targeting GLP-1 alone, which is why tirzepatide produces better weight loss results than semaglutide (Wegovy/Ozempic).
How Retatrutide Works (Triple Agonist)?
Retatrutide adds a third receptor to the mix: the glucagon receptor. This is a key differentiator that may explain the enhanced weight loss observed in early trials.
Glucagon Receptor: Glucagon is often called the “opposite of insulin.” When activated, the glucagon receptor increases energy expenditure by promoting the breakdown of stored fat and glycogen. It may also help maintain lean muscle mass during weight loss.
By combining all three pathways, retatrutide attacks obesity from multiple angles: reducing appetite (GLP-1), improving metabolism (GIP), and increasing calorie burning (glucagon).
Pro Tip: The glucagon receptor activation is what makes retatrutide unique. Early data suggests this may help preserve lean muscle mass during weight loss, a common concern with GLP-1 medications.
Weight Loss Results: Clinical Trial Data Compared
Both medications show impressive weight loss results, though direct comparison requires caution due to differences in trial design.
Retatrutide Phase 2 Results
The Phase 2 obesity trial (published in NEJM, 2023) showed remarkable results across dose levels:
| Dose | Weight Loss at 48 Weeks |
|---|---|
| 4mg | 17.5% |
| 8mg | 22.8% |
| 12mg | 24.2% |
At the 12mg dose, participants lost an average of 58 pounds over 48 weeks. Some participants lost over 30% of their body weight.
Tirzepatide SURMOUNT-1 Results
The SURMOUNT-1 Phase 3 trial (published in NEJM, 2022) enrolled 2,539 adults with obesity. After 72 weeks:
| Dose | Weight Loss at 72 Weeks |
|---|---|
| 5mg | 15.0% |
| 10mg | 19.5% |
| 15mg | 22.5% |
At 15mg, 63% of participants achieved at least 20% weight loss, and 83% achieved at least 10% weight loss.
Important Context for Comparison
While retatrutide’s 24.2% appears to edge out tirzepatide’s 22.5%, several factors complicate direct comparison:
- Trial Phase: Retatrutide data comes from Phase 2 (smaller, shorter trials often show more optimistic results) while tirzepatide data comes from Phase 3 (larger, more rigorous trials)
- Duration: Retatrutide was 48 weeks vs tirzepatide’s 72 weeks
- Sample Size: Retatrutide had 338 participants vs tirzepatide’s 2,539
- Patient Population: Different baseline characteristics and selection criteria
We’ll have a clearer picture once retatrutide Phase 3 results are published. Eli Lilly is also conducting a head-to-head trial, though results aren’t expected for several years.
A1C Reduction and Diabetes Management
Both medications show significant benefits for type 2 diabetes, which isn’t surprising given that incretin hormones naturally regulate blood sugar.
Diabetes Efficacy Data
| Metric | Retatrutide | Tirzepatide |
|---|---|---|
| A1C Reduction | -2.02% (12mg dose) | -2.1% (15mg dose) |
| Trial | Phase 2 T2D | SURPASS-2 |
| FDA Approval | Not approved | Approved (Mounjaro) |
Both medications achieve A1C reductions well beyond the 1% threshold typically considered clinically meaningful. Many patients on either medication achieve A1C levels below 7% or even in the non-diabetic range.
For patients with type 2 diabetes, tirzepatide (as Mounjaro) is the clear choice right now because it’s the only FDA-approved option.
Side Effects: Which Is Better Tolerated?
Gastrointestinal side effects are common with both medications, which is expected given their mechanism of action. However, the rates differ significantly between trials.
Side Effect Comparison
| Side Effect | Retatrutide (Phase 2) | Tirzepatide (Phase 3) |
|---|---|---|
| Nausea | 60-80% (high doses) | 18-29% (dose-dependent) |
| Diarrhea | Common | 21% |
| Vomiting | Common | 11% |
| Discontinuation Rate | 6-16% | 4.3-7.1% |
Why Retatrutide Shows Higher Side Effect Rates?
The higher side effect rates seen with retatrutide may not tell the whole story. There are important reasons why Phase 2 data often shows more side effects:
Aggressive Dosing: Phase 2 trials often use faster dose escalation to find the optimal therapeutic range. The Phase 3 program may use gentler titration schedules.
Smaller Sample Size: With only 338 participants, individual variations have more impact on percentage rates.
Novel Mechanism: The glucagon receptor activation may contribute additional GI effects, though the body often adapts over time.
Real-world tolerability of tirzepatide has proven quite good, with most users reporting that side effects improve after the first few weeks of dose escalation.
Availability: When Can You Get Each Medication?
This is where the most significant practical difference lies. Availability determines whether you can actually access these treatments today.
Tirzepatide: Available Now
Tirzepatide is FDA-approved and available by prescription across the United States. You can get it through:
- Your primary care doctor or endocrinologist
- Obesity medicine specialists
- Telehealth weight loss programs
Telehealth Options for Tirzepatide Access
Several telehealth platforms make it easy to get evaluated and prescribed tirzepatide from home. Based on our research, here are reputable options:
Ro Body Program: Offers both brand-name and compounded tirzepatide options with insurance concierge support. Membership starts at $145/month plus medication costs.
Hims/Hers: Major telehealth provider with comprehensive GLP-1 programs and physician consultations.
Found: Weight loss focused platform at $129/month membership plus medication costs.
Tirzepatide Pricing
The list price for tirzepatide (Mounjaro/Zepbound) runs $1,000-$1,350 per month without insurance. However, many patients pay significantly less:
- With commercial insurance: Copays range from $0-$550 depending on coverage
- Manufacturer savings card: Eligible patients can save up to $550/month
- Compounded options: Some telehealth providers offer compounded tirzepatide at lower costs
Disclaimer: Compounded medications are not FDA-approved and may not be available in all states. Only FDA-approved Mounjaro and Zepbound have undergone full regulatory review.
Retatrutide: Clinical Trials Only
Retatrutide is not available commercially. The only way to access it currently is through clinical trial enrollment.
How to Find Retatrutide Clinical Trials?
If you’re interested in potentially accessing retatrutide before FDA approval:
- Visit ClinicalTrials.gov and search for “retatrutide TRIUMPH”
- Review active trials and eligibility criteria
- Contact trial sites near your location
- Complete screening to determine eligibility
Clinical trial participants typically receive the medication free of charge and have access to regular medical monitoring throughout the study.
Expected Approval Timeline
Based on current Phase 3 trial timelines and typical FDA review periods, here’s a rough timeline:
- 2026: TRIUMPH Phase 3 trials ongoing
- Late 2026 – Early 2027: Phase 3 results expected
- 2027: FDA submission anticipated (if results positive)
- Late 2027 – 2028: Potential FDA approval
These timelines can shift based on trial results, FDA questions, or manufacturing readiness.
Which Should You Choose: Retatrutide or Tirzepatide?
The decision comes down to one fundamental question: Do you need treatment now, or can you wait 2-3 years?
Choose Tirzepatide If:
- You need an effective weight loss medication now
- You want an FDA-approved medication with established safety data
- You have type 2 diabetes and need glycemic control
- You prefer a proven treatment over waiting for something potentially better
- You have insurance coverage or can afford the cost
Consider Waiting for Retatrutide If:
- You’re not in urgent need of weight loss treatment
- You’re willing to enroll in a clinical trial
- You want to see Phase 3 results before committing to any medication
- You’re interested in the potential benefits of triple agonist therapy
Can You Start Tirzepatide Now and Switch Later?
Yes, this is a reasonable approach for many patients. There’s no evidence that taking tirzepatide would prevent you from trying retatrutide later if it becomes available and you prefer to switch.
However, switching protocols haven’t been studied, and your doctor would need to determine appropriate timing and dosing for any transition.
Our Recommendation: For most people seeking weight loss treatment in 2026, tirzepatide is the clear choice. It’s proven, available, and delivers excellent results. Don’t let the promise of a potentially better future medication prevent you from getting effective treatment today.
Frequently Asked Questions
Is retatrutide better than tirzepatide for weight loss?
Based on early Phase 2 trial data, retatrutide showed 24.2% weight loss compared to tirzepatide’s 22.5% in Phase 3 trials. However, these results come from different studies and cannot be directly compared. We won’t know for certain until a head-to-head trial is completed. Both medications produce clinically significant weight loss.
When will retatrutide be FDA approved?
Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH program). If trials are successful, FDA approval could come in late 2027 or 2028. However, these timelines are estimates and could shift based on trial outcomes and regulatory review speed.
Can I get retatrutide now?
Retatrutide is only available through clinical trial enrollment. It is not approved for commercial sale anywhere in the world. You can search for active trials at ClinicalTrials.gov by looking for ‘retatrutide TRIUMPH’ trials.
What is the difference between a triple and dual agonist?
A dual agonist like tirzepatide activates two hormone receptors (GLP-1 and GIP). A triple agonist like retatrutide activates three receptors (GLP-1, GIP, and glucagon). The additional glucagon receptor activation may increase energy expenditure and fat burning.
Can you take retatrutide and tirzepatide together?
No. These medications should not be combined. Taking multiple GLP-1 agonists together would significantly increase the risk of serious side effects without proven additional benefit. Your doctor would prescribe one or the other, not both.
Does retatrutide have more side effects than tirzepatide?
Phase 2 trials showed higher GI side effect rates with retatrutide (60-80% nausea at high doses) compared to tirzepatide Phase 3 data (18-29% nausea). However, Phase 2 trials often use aggressive dosing. Real-world tolerability may be better once optimal dosing protocols are established.
How much does tirzepatide cost?
Tirzepatide (Mounjaro/Zepbound) has a list price of $1,000-$1,350 per month. With insurance, copays typically range from $0-$550. Eli Lilly offers a savings card for eligible patients that can reduce costs by up to $550 per month.
Is there a head-to-head trial comparing retatrutide and tirzepatide?
As of 2026, no completed head-to-head trial exists. Eli Lilly is conducting comparative studies, but results are not expected for several years. Current comparisons are based on separate trials with different designs.
Final Verdict: Retatrutide vs Tirzepatide
After analyzing all available clinical data, here’s my assessment:
Tirzepatide wins for now. It’s FDA-approved, commercially available, and has helped millions of patients achieve significant weight loss. The 22.5% average weight loss in clinical trials translates to life-changing results for many people.
Retatrutide shows promise for the future. The 24.2% weight loss in Phase 2 trials and the innovative triple-agonist mechanism are exciting. But promise isn’t the same as proven results, and investigational medications can disappoint in larger Phase 3 trials.
If you’re considering weight loss medication in 2026, don’t wait for the perfect option. Tirzepatide is an excellent treatment available today. You can always consider switching to retatrutide (or other future medications) once they become available if they prove to be superior.
Talk to your doctor about whether tirzepatide is appropriate for your situation. If you don’t have easy access to a physician, telehealth platforms offer convenient consultations and can prescribe appropriate medications.
This review is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any weight-loss medication. Results vary by individual, and these medications may not be appropriate for everyone.